drugset / Trial / NCT01260545
Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies
Non-randomizedSingle-groupOpen-labelSupportive care
Summary
The purpose of this study is to examine the safety and tolerability of CA-18C3 in subjects with hematologic malignancies, as well as look at the preliminary efficacy of IL-1alpha blockade.
Timeline
- Start
- 2011-04-30
- Primary completion
- 2012-06-30
- Completion
- 2012-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bermekimab | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Bermekimab | Monoclonal antibody | 3.75 mg/kg | Intravenous |